Objectives: First-generation protease-inhibitors (PIs) had suboptimal efficacy in GT-1 patients with 25 advanced liver disease, and those who failed may need urgent retreatment. Our objective was to 26 analyze the real-life efficacy of interferon (IFN)-free retreatment after PI-failure, and the role of 27 genotypic-resistance-testing (GRT) in guiding retreatment choice.
The frequent development of NS3 resistance associated substitutions (RASs) at failure limits 50 retreatment options with protease inhibitors (PIs) for patients who previously failed a PI containing 51 regimen. To avoid cross-resistance both AASLD and EASL recommend to use a combination of an 52 NS5A-inhibitor plus sofosbuvir (SOF)(1, 2), without performing any baseline genotypic-resistance-53 testing (GRT). However, in retreatment settings, GRT can be clinically helpful in providing 54 additional confidence for NS5A-inhibitors use, accounting for possible presence of natural NS5A-
55
RASs (1, 3, 4) , and in evaluating alternative 2 nd line regimens besides those suggested by guidelines.
56
Very few reports are available on real-life retreatment of PI-experienced patients(5-7), and on the 57 use, and utility, of baseline HCV-GRT in this setting.
58

METHODS
59
We analyzed the efficacy of several IFN-free retreatment strategies chosen for 121 patients with (Table S1 ).
63
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